Scarica l'app Stockscreener
16.23
4.98%
-0.85
Dopo l'orario di chiusura:
16.20
-0.03
-0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Eyepoint Inc Borsa (EYPT) Ultime notizie
Will EyePoint Pharmaceuticals Inc. stock remain a Wall Street favoriteGrip and Outsole Review & road comfort picks for daily use - ulpravda.ru
How sustainable is EyePoint Pharmaceuticals Inc. stock dividend payoutMarket Performance Report & Safe Entry Point Identification - ulpravda.ru
How EyePoint Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Gainers & Real-Time Volume Analysis Alerts - ulpravda.ru
Aug Ideas: Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikes2025 Year in Review & Safe Investment Capital Preservation Plans - ulpravda.ru
Is EyePoint Pharmaceuticals Inc. stock affected by interest rate hikesPortfolio Value Summary & High Conviction Buy Zone Alerts - ulpravda.ru
Will EyePoint Pharmaceuticals Inc. stock continue dividend increasesMarket Volume Report & Entry Point Confirmation Alerts - ulpravda.ru
Eyepoint Insider Sold Shares Worth $727,319, According to a Recent SEC Filing - MarketScreener
EyePoint Chief Medical Officer Sells All Common Stock Holdings - TradingView — Track All Markets
EyePoint, Inc.Common Stock (NQ: EYPT - FinancialContent
Mizuho reiterates Outperform rating on EyePoint stock with $33 target - Investing.com
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target - Investing.com Nigeria
Mizuho reiterates Outperform rating on EyePoint stock with $33 target By Investing.com - Investing.com India
RBC Capital reiterates Outperform rating on EyePoint stock at $39 target By Investing.com - Investing.com India
EyePoint’s Phase 3 trials for DURAVYU in wet AMD on track for mid-2026 data - Investing.com
EyePoint, Inc. Advances DURAVYU in Pivotal Phase 3 Trials for Wet AMD and DME with Key Milestones Expected in 2026 - Quiver Quantitative
Uveitis Treatment Market to Reach US$ 1,258.35million | CAGR - openPR.com
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026 - GlobeNewswire Inc.
PRN_FinancialWrapper | PR NewswireEyePoint, Inc.Common Stock (Nasdaq:EYPT) Stock Quote - FinancialContent
Can EyePoint Pharmaceuticals Inc. stock maintain growth trajectory2026 world cup usa national team group stage star players transition play group prediction guide - ulpravda.ru
EYPT (EyePoint) Days Payable : 1,883.28 (As of Sep. 2025) - GuruFocus
Is EyePoint Pharmaceuticals the Next Sleeper Stock Legend or Just Overhyped Noise? - AD HOC NEWS
Institutional Investors in EyePoint, Inc. (NASDAQ:EYPT) See US$67m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them. - 富途牛牛
EyePoint (EYPT) price target increased by 10.87% to 36.80 - MSN
What drives EyePoint Pharmaceuticals Inc PV3B stock priceSell Signals and Alerts & Top Analyst Picks Available for Free - earlytimes.in
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.1%Here's What Happened - MarketBeat
The Year-End 2025 Biotech Rally And What It Means For 2026 - Benzinga
Understanding the Setup: (EYPT) and Scalable Risk - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Analysts - MarketBeat
127,489 Shares in Eyepoint Pharmaceuticals, Inc. $EYPT Purchased by Corient Private Wealth LLC - MarketBeat
Why EyePoint (EYPT) Is Up 9.6% After Upbeat Earnings Revisions And Momentum SignalsAnd What's Next - Sahm
EyePoint (EYPT): Assessing Valuation After Earnings Upgrades and Strong Momentum-Driven Share Gains - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.2%Time to Sell? - MarketBeat
EyePoint Earnings Notes - Trefis
EyePoint (EYPT) Is Up 9.01% in One Week: What You Should Know - Yahoo Finance
3 Biotech Stocks Wall Street Analysts Are Bullish on for 2026 - Zacks Investment Research
Would You Still Hold EyePoint Stock If It Fell 30%? - Trefis
Will EyePoint Pharmaceuticals Inc. stock rally after Fed decisionsWeekly Risk Summary & Technical Analysis for Trade Confirmation - Улправда
EyePoint (EYPT) Price Target Increased by 10.87% to 36.80 - Nasdaq
Is EyePoint Pharmaceuticals Inc. stock dividend yield sustainable2025 Technical Overview & Expert Approved Momentum Ideas - Улправда
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Rating Increased to Strong-Buy at TD Cowen - MarketBeat
Why (EYPT) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside - Barchart.com
Can EyePoint Pharmaceuticals Inc. stock resist market sell offsMarket Risk Summary & High Conviction Buy Zone Picks - Улправда
Is EyePoint Pharmaceuticals Inc a good long term investmentOptions Trading Strategies & Free Tap Rapid Wealth - earlytimes.in
Is EyePoint Pharmaceuticals Inc. stock overvalued by current metricsPortfolio Value Report & Weekly High Conviction Trade Ideas - Улправда
Will EyePoint Pharmaceuticals Inc. stock reach all time highs in 2025 - DonanımHaber
Inflation Data: How EyePoint Pharmaceuticals Inc. (PV3B) stock compares with market leadersJuly 2025 Sentiment & Community Trade Idea Sharing Platform - Улправда
How EyePoint Pharmaceuticals Inc. stock reacts to oil pricesWeekly Stock Recap & Expert Approved Trade Ideas - DonanımHaber
Should I hold or sell EyePoint Pharmaceuticals Inc. stock in 2025July 2025 Rallies & Low Risk Growth Stock Ideas - Улправда
Support Test: Will EyePoint Pharmaceuticals Inc. stock see PE expansionDividend Hike & Low Risk Entry Point Guides - Улправда
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Globe and Mail
EyePoint, Inc. CEO Jay S. Duker to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Eye disease drug developer to present at major healthcare conf - Stock Titan
EyePoint (STU:PV3B) OCF Margin % : -6,144.59% (As of Sep. 2025) - GuruFocus
EyePoint reports inducement grants under NASDAQ listing rule - MSN
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 5.8% HigherWhat's Next? - MarketBeat
EyePoint (EYPT) Grants Stock Options to New Employees as Inducem - GuruFocus
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):